Atea Pharmaceuticals Inc (AVIR)

Jun 15, 2026

Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN

Jun 15, 2026

Jun 10, 2026

Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN

Jun 10, 2026

Jun 09, 2026

Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance

Jun 09, 2026

Jun 08, 2026

Atea Pharmaceuticals (AVIR) Rallies 1.65% as Shares Test Key Resistance Near $4.54Scalping Stock Signals - newsline.com

Jun 08, 2026

Jun 07, 2026

Atea Pharmaceuticals (AVIR) Declines 3.85% as Shares Approach Key Support LevelPCR Mean Reversion - newsline.com

Jun 07, 2026

Jun 05, 2026

AVIR Stock Chart | ATEA PHARMACEUTICALS INC (NASDAQ:AVIR) - ChartMill

Jun 05, 2026

Jun 03, 2026

AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Jun 03, 2026

May 29, 2026

Atea PharmaceuticalsI'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR) - Seeking Alpha

May 29, 2026

May 28, 2026

Atea Pharmaceuticals Q1 earnings call highlights - MSN

May 28, 2026

May 28, 2026

Atea Pharmaceuticals Q1 2026 Earnings: Narrower Loss Beats Expectations; Stock Edges HigherFiscal Year Earnings - The Legal Advocate

May 28, 2026

May 27, 2026

Atea Pharmaceuticals Rises After Hepatitis C Data; 2026 Readouts Eyed - Bez Kabli

May 27, 2026

May 27, 2026

Atea presents hepatitis C drug interaction data at EASL - Investing.com UK

May 27, 2026

May 27, 2026

Atea Pharmaceuticals Presents New Drug-Drug Interaction - GlobeNewswire

May 27, 2026

May 27, 2026

Atea Pharmaceuticals (AVIR) Holds Steady Near Support Amid Flat Trading SessionPre-Earnings Momentum - newsline.com

May 27, 2026

May 25, 2026

Atea Pharmaceuticals (AVIR) Gains 4.25% as Biotech Sentiment Lifts the StockValue Factor - Newser

May 25, 2026

May 25, 2026

Spotlight On Atea Pharmaceuticals And 2 Other Prominent Penny Stocks - Yahoo Finance

May 25, 2026

May 22, 2026

Atea Pharmaceuticals (AVIR) Edges Higher Amid Renewed Investor InterestBuffered ETF - Newser

May 22, 2026

May 22, 2026

Atea Pharmaceuticals (AVIR) Gains 4.25% as Stock Tests Key Resistance LevelActive ETF Flow - The Legal Advocate

May 22, 2026

May 22, 2026

Atea Pharmaceuticals (AVIR) Shows Modest Uptick, Holding Above Key SupportCommunity Pattern Alerts - Newser

May 22, 2026

May 21, 2026

Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock By Investing.com - Investing.com Canada

May 21, 2026

May 21, 2026

Atea Pharmaceuticals director Polly Murphy buys $25,446 in stock - Investing.com

May 21, 2026

May 21, 2026

Atea Pharmaceuticals (AVIR) director buys 6,100 shares of stock - Stock Titan

May 21, 2026

May 20, 2026

Atea (AVIR) director adds 6,100 shares in open-market purchase - Stock Titan

May 20, 2026

May 19, 2026

Atea Pharma (AVIR) Stock: Up +1.69%, Key Resistance at $4.42 2026-05-19Community Exit Signals - Newser

May 19, 2026

May 19, 2026

Here's Why We're Watching Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance

May 19, 2026

May 18, 2026

Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN

May 18, 2026

May 18, 2026

Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss By Investing.com - Investing.com South Africa

May 18, 2026

May 18, 2026

Earnings call transcript: Atea Pharmaceuticals Q1 2026 reveals stock plunge after EPS miss - Investing.com Nigeria

May 18, 2026

May 18, 2026

Morgan Stanley Maintains Atea Pharmaceuticals(AVIR.US) With Hold Rating, Cuts Target Price to $4.1 - Moomoo

May 18, 2026

May 15, 2026

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround - Yahoo Finance

May 15, 2026

May 14, 2026

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR) - The Globe and Mail

May 14, 2026

May 14, 2026

Atea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis Pipeline - Sahm

May 14, 2026

May 14, 2026

We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully - Moomoo

May 14, 2026

May 13, 2026

Atea Pharmaceuticals Sets Up Catalyst-Rich 2026 Earnings Call - TipRanks

May 13, 2026

May 13, 2026

Atea Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance

May 13, 2026

May 13, 2026

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q1 2026 Earnings Call Transcript - Insider Monkey

May 13, 2026

May 13, 2026

Atea Pharmaceuticals Announces Three Accepted Abstracts for Presentation at EASL Congress 2026 - Quiver Quantitative

May 13, 2026

May 13, 2026

Atea Pharmaceuticals to Present Three Abstracts at EASL - GlobeNewswire

May 13, 2026

May 13, 2026

Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027 - MSN

May 13, 2026

May 13, 2026

New hepatitis C and E drug data headed to EASL 2026 congress - Stock Titan

May 13, 2026

May 12, 2026

Atea Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:AVIR) 2026-05-12 - Seeking Alpha

May 12, 2026

May 12, 2026

Earnings call transcript: Atea Pharmaceuticals Q1 2026 reports slight EPS miss, stock dips - Investing.com Nigeria

May 12, 2026

May 12, 2026

Atea Pharmaceuticals Q1 Earnings Call Highlights - Yahoo Finance

May 12, 2026

May 12, 2026

Atea Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript - Benzinga

May 12, 2026

May 12, 2026

[10-Q] Atea Pharmaceuticals, Inc. Quarterly Earnings Report - Stock Titan

May 12, 2026

May 12, 2026

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results - TradingView

May 12, 2026

May 12, 2026

Atea Pharmaceuticals reports Q1 2026 net loss $45.4M, cash & marketable securities $256.0M - TradingView

May 12, 2026